Can science meet the challenges of the HCV pandemic: new treatment options for chronic hepatitis C.

Abstract excerpt

New treatment options for chronic hepatitis C (HCV) infection are examined. Studies show the efficacy of interferon alfa-2b in normalization of serum alanine aminotransferase and histological improvement in necroinflammatory liver disease. However, 70 to 80 percent experiencing normalization usually relapse within 1 year after treatment. Ten to 20 percent will have a sustained response lasting at least 3 years....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antiviral Agents
• Share to Clinical Trials as Topic
• Share to Drug Therapy, Combination